SEC ownership of Roivant Sciences Ltd.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001635088.

Comparable stake leader

FMR LLC

Disclosed value leader

FMR LLC

Comparable rows

50/50

Latest evidence

16 Apr 2026

Top shareholders Insider holders Latest transactions
Public ticker
ROIV on Nasdaq
Parsed ownership sources
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
FMR LLC
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
FMR LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
16 Apr 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001635088
Issuer location
London

Ownership snapshot

Top shareholders of Roivant Sciences Ltd. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
16 Apr 2026
13F 13D/G 3/4/5 Lead comparable stake: 10% 13D/G row: FMR LLC Showing 1-8 of 50 holder rows.

Quick read

FMR LLC leads the comparable SEC ownership view at 10%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FMR LLC's linked filing trail.
Comparable ownership Top 5
FMR LLC 10%
MORGAN STANLEY 6.9%
QVT Financial LP 4.3%
Vivek Ramaswamy 3.6%
VIKING GLOBAL INVESTORS LP 3.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FMR LLC
13F 13D/G
Company
13F 13D/G
10%
from 13D/G
$2,160,080,715
77,981,253 shares
 — 31 Mar 2026
MORGAN STANLEY
13F 13D/G
Company
13F 13D/G
6.9%
from 13D/G
$1,435,644,662
51,828,325 shares
 — 31 Mar 2026
QVT Financial LP
13F 13D/G 3/4/5
Company · Director by Deputization
13F 13D/G 3/4/5
4.3%
from 13D/G
$696,966,265
25,161,237 shares
 — 31 Mar 2026
Vivek Ramaswamy
3/4/5 13D/G
10%+ Owner · Ramaswamy Vivek
3/4/5 13D/G
3.6%
from 13D/G
$1,012,161,165
69,161,839 shares
mixed-class rows
 -$141,422,469 11 Dec 2025
VIKING GLOBAL INVESTORS LP
13D/G 3/4/5 13F
10%+ Owner · Company
13D/G 3/4/5 13F
3.4%
$356,989,793
23,594,831 shares
 -$161,027,803 30 Sep 2025
SB INVESTMENT ADVISERS (UK) LTD
13D/G 13F
SB Investment Advisers (UK) Limited · Company
13D/G 13F
2.3%
$357,488,273
16,413,603 shares
 -$520,575,193 31 Dec 2025
Mayukh Sukhatme
3/4/5
President & CIO, Director
3/4/5
2.6%
$405,304,288
18,677,617 shares
 -$38,507,032 30 Mar 2026
Matthew Gline
3/4/5
CEO, Director
3/4/5
2.3%
$488,025,142
16,736,116 shares
 -$46,123,053 16 Apr 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$712,791,341.

Buys
$49,957
Insiders: 1
Sells
$712,841,298
Insiders: 12
Net
-$712,791,341
Shares: -33,121,502
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 3,315 Shares: 33,124,817
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 1,015,173 $0 $29,575,956 -$29,575,956
3-6 0 16,633,810 $0 $406,225,021 -$406,225,021
6-9 3,315 12,257,812 $49,957 $238,030,315 -$237,980,358
9-12 0 3,218,022 $0 $39,010,006 -$39,010,006

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 25 reporting-owner rows connected to Roivant Sciences Ltd.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
25
Largest Forms 3/4/5 holder
Dexcel Pharma Technologies Ltd.
Net 12M change
-$712,791,342
Latest report
20 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Dexcel Pharma Technologies Ltd. 10%+ Owner $1,064,491,735 Mixed 10 Nov 2022
Vivek Ramaswamy 10%+ Owner $1,012,161,165 -$141,422,469 -12% Mixed 11 Dec 2025
SVF Investments (UK) Ltd 10%+ Owner $755,877,753 Mixed 28 Sep 2023
Sumitomo Chemical Co., Ltd. 10%+ Owner $737,448,709 Mixed 22 Jun 2023
Matthew Gline CEO, Director $488,025,142 -$46,123,053 -8.6% Filing P/S 16 Apr 2026
Mayukh Sukhatme President & CIO, Director $405,304,288 -$38,507,032 -8.7% Mixed 30 Mar 2026
Daniel Allen Gold Director $400,874,218 -$98,028,232 -20% Filing P/S 11 Feb 2026
Keith S. Manchester Director $400,874,218 -$98,028,232 -20% Filing P/S 11 Feb 2026
QVT Financial LP Director by Deputization $400,874,218 -$98,028,232 -20% Filing P/S 11 Feb 2026
Frank Torti President and Vant Chair $294,610,310 -$82,039,460 -22% Mixed 31 Mar 2026
Eric Venker President & Immunovant CEO $171,694,712 -$97,986,179 -36% Mixed 20 May 2026
VIKING GLOBAL PERFORMANCE LLC 10%+ Owner $133,352,577 Mixed 22 Jun 2023
VIKING GLOBAL INVESTORS LP 10%+ Owner $133,352,577 Mixed 22 Jun 2023
Benjamin Zimmer President, Roivant Health $12,083,532 Mixed 01 Oct 2021
Richard Pulik Cfo $7,715,807 -$9,122,307 -54% Median 20 May 2026
Ilan Oren Director $3,330,343 Median 17 Apr 2026
Jennifer Humes Chief Accounting Officer $3,140,182 -$384,073 -11% Median 20 Apr 2026
James C. Momtazee Director $3,030,518 Median 17 Apr 2026
Rakhi Kumar Chief Accounting Officer $1,739,920 Mixed 20 Feb 2025
Meghan Fitzgerald Director $1,179,334 -$1,921,500 -62% Filing P/S 26 Mar 2026

Recent insider transactions for Roivant Sciences Ltd.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Eric Venker ROIV Common Shares Sale -11% $6,054,000 $30.27 -200,000 1,613,063 22 May 2026 Direct
Eric Venker ROIV Common Shares Options Exercise 12.4% 200,000 1,813,063 22 May 2026 Direct
Eric Venker ROIV Stock Option (Right to Buy) Options Exercise -4.31% -200,000 4,444,834 22 May 2026 Direct
Eric Venker ROIV Common Shares Tax liability -2.09% -34,483 1,613,063 20 May 2026 Direct
Richard Pulik ROIV Common Shares Tax liability -6.37% -18,962 278,549 20 May 2026 Direct
Eric Venker ROIV Common Shares Sale -10.8% $5,918,000 $29.59 -200,000 1,647,546 20 Apr 2026 Direct
Eric Venker ROIV Common Shares Options Exercise 12.1% 200,000 1,847,546 20 Apr 2026 Direct
Eric Venker ROIV Stock Option (Right to Buy) Options Exercise -4.13% -200,000 4,644,834 20 Apr 2026 Direct
Richard Pulik ROIV Common Shares Award 25.6% 60,644 297,511 20 Apr 2026 Direct
Richard Pulik ROIV Stock Option (Right to Buy) Award 84,026 84,026 20 Apr 2026 Direct
Jennifer Humes ROIV Common Shares Award 34.6% 29,173 113,364 20 Apr 2026 Direct
Jennifer Humes ROIV Stock Option (Right to Buy) Award 27,157 27,157 20 Apr 2026 Direct
Ilan Oren ROIV Common Shares Tax liability -0.08% -95 120,229 17 Apr 2026 Direct
Ilan Oren ROIV Common Shares Award 0.75% 896 120,324 17 Apr 2026 Direct
Melissa B. Epperly ROIV Common Shares Award 4.24% 670 16,474 17 Apr 2026 Direct
James C. Momtazee ROIV Common Shares Tax liability -0.09% -94 109,405 17 Apr 2026 Direct
James C. Momtazee ROIV Common Shares Award 0.43% 469 109,499 17 Apr 2026 Direct
Matthew Gline ROIV Common Shares Sale -1.7% $8,449,810 $29.16 -289,774 16,736,116 16 Apr 2026 Direct
Jennifer Humes ROIV Common Shares Sale -13.8% $384,073 $28.37 -13,538 84,191 08 Apr 2026 Direct
Frank Torti ROIV Common Shares Tax liability -1.17% -160,035 13,576,512 31 Mar 2026 Direct
Matthew Gline ROIV Common Shares Tax liability -1.76% -304,684 17,025,890 31 Mar 2026 Direct
Mayukh Sukhatme ROIV Common Shares Tax liability -0.99% -187,512 18,677,617 31 Mar 2026 Direct
Matthew Gline ROIV Common Shares Tax liability -0.31% -53,826 17,330,574 30 Mar 2026 Direct
Matthew Gline ROIV Common Shares Options Exercise 0.56% 97,319 17,384,400 30 Mar 2026 Direct
Matthew Gline ROIV Capped Value Appreciation Rights Options Exercise -100% -2,178,150 0 30 Mar 2026 Direct
Mayukh Sukhatme ROIV Common Shares Tax liability -0.16% -29,809 18,865,129 30 Mar 2026 Direct
Mayukh Sukhatme ROIV Common Shares Options Exercise 0.31% 58,391 18,894,938 30 Mar 2026 Direct
Mayukh Sukhatme ROIV Capped Value Appreciation Rights Options Exercise -100% -1,306,889 0 30 Mar 2026 Direct
Meghan FitzGerald ROIV Common Shares Sale -62% $1,921,500 $27.45 -70,000 42,963 26 Mar 2026 Direct
Meghan FitzGerald ROIV Common Shares Options Exercise 162.9% 70,000 112,963 26 Mar 2026 Direct
Meghan FitzGerald ROIV Stock Option (Right to Buy) Options Exercise -59% -70,000 48,578 26 Mar 2026 Direct
Richard Pulik ROIV Common Shares Tax liability -0.65% -1,546 236,867 20 Mar 2026 Direct
Jennifer Humes ROIV Common Shares Tax liability -12.9% -14,526 97,729 20 Mar 2026 Direct
Eric Venker ROIV Common Shares Sale -10.8% $5,648,000 $28.24 -200,000 1,647,546 17 Mar 2026 Direct
Eric Venker ROIV Common Shares Options Exercise 12.1% 200,000 1,847,546 17 Mar 2026 Direct
Eric Venker ROIV Stock Option (Right to Buy) Options Exercise -3.96% -200,000 4,844,834 17 Mar 2026 Direct
Melissa B. Epperly ROIV Common Shares Sale -72.6% $1,200,573 $28.68 -41,861 15,804 16 Mar 2026 Direct
Frank Torti ROIV Common Shares Sale -4.1% $16,159,099 $27.51 -587,390 13,736,547 23 Feb 2026 Direct
Frank Torti ROIV Common Shares Options Exercise 4.28% 587,390 14,323,937 23 Feb 2026 Direct
Frank Torti ROIV Stock Option (Right to Buy) Options Exercise -16.3% -587,390 3,026,184 23 Feb 2026 Direct
Richard Pulik ROIV Common Shares Tax liability -0.42% -1,000 238,413 20 Feb 2026 Direct
Eric Venker ROIV Common Shares Tax liability -0.43% -7,051 1,647,546 20 Feb 2026 Direct
Frank Torti ROIV Common Shares Sale -6.87% $27,492,362 $27.15 -1,012,610 13,736,547 20 Feb 2026 Direct
Frank Torti ROIV Common Shares Options Exercise 7.37% 1,012,610 14,749,157 20 Feb 2026 Direct
Frank Torti ROIV Stock Option (Right to Buy) Options Exercise -21.9% -1,012,610 3,613,574 20 Feb 2026 Direct
Frank Torti ROIV Common Shares Sale -9.25% $38,388,000 $27.42 -1,400,000 13,736,547 19 Feb 2026 Direct
Frank Torti ROIV Common Shares Options Exercise 10.2% 1,400,000 15,136,547 19 Feb 2026 Direct
Frank Torti ROIV Stock Option (Right to Buy) Options Exercise -23.2% -1,400,000 4,626,184 19 Feb 2026 Direct
Eric Venker ROIV Common Shares Sale -10.8% $5,298,000 $26.49 -200,000 1,654,597 13 Feb 2026 Direct
Eric Venker ROIV Common Shares Options Exercise 12.1% 200,000 1,854,597 13 Feb 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .